Intranasal Insulin in Frontotemporal Dementia (FTD)

Summary

This project will study intranasal (IN) insulin in Frontotemporal dementia (FTD) in 12 patients. Study Investigators aim to evaluate the feasibility of the EXAMINER cognitive battery as a cognitive outcome measure in FTD, the ability of the HealthPartners Center for Memory and Aging's ability to sufficiently recruit subjects with FTD, and the safety of IN regular insulin administered 20 IU twice per day in two specific variants of FTD (behavioral variant frontotemporal dementia (bv-FTD), semantic dementia (SD)) over a 4 week period.

Timeline

Start

2019-09-09

Primary completion

2020-02-26

Completion

2023-05-15

Outcome

Outcome not reported

Stopped: “COVID - unable to restart after restrictions were lifted”

Drugs

Indications